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A. Raper/3-E.R. Mohler/1, 2-J.M. Gelfand 1-Department of Dermatology,
University of Pennsylvania, Philadelphia, PA; 2-Center for Clinical
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Severe psoriasis is a risk factor for cardiovascular (CV) disease beyond traditional
risk factors. The mechanism of atherogenesis in psoriasis, however, remains
unknown. Recent findings suggest that cell membrane vesicles, or microparticles,
which are released upon cell activation or apoptosis, are associated with CV
disease andmay play a pathogenic role. Levels of microparticles, particularly from
endothelial cells and platelets, are elevated in patients with cardiovascular
disorders, metabolic syndrome, other inflammatory diseases, autoimmune
conditions and have recently been shown to be predictive of CV outcomes. To
understand if microparticles may serve as a potential link between psoriasis and
CV disease, we measured absolute circulating microparticle levels, concentrations
and types (endothelial- versus platelet-derived) of microparticles in blood samples
from psoriasis patients (n¼ 20) and compared them to healthy controls (n¼ 41).
Platelet-poor plasma was separated from whole blood after rigorous high-speed
centrifugation for microparticle analysis. Microparticles were fluorescently labeled
and characterized by flow cytometry. We found higher absolute microparticle
levels (2.6-fold; po0.01) and microparticle concentration (per uL, 50-fold;
p¼ 0.01) in psoriasis compared to healthy controls, which persisted after
adjustment for traditional cardiovascular disease risk factors. Characterization of
the microparticles revealed a predominance of endothelial-, platelet-, and T
lymphocyte-derived microparticles, all of which were present in higher absolute
levels in psoriasis patients compared to healthy controls (po0.01, po0.01,
p¼ 0.03, respectively) beyond traditional risk factors. Our findings of increased
microparticle levels, independent of cardiovascular risk factors, in psoriasis
suggests that the presence of increased endothelial cell and platelet activation with
turnover may contribute to the heightened atherogenesis observed in psoriasis.
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Deferasirox for Porphyria Cutanea Tarda: A pilot study
1-K. A. Nezafati/2-R. Yalamanchili/3-M. Ashe-Randolph/4-A. G. Pandya
1-4 - The University of Texas Southwestern Medical Center at Dallas
Porphyria cutanea tarda (PCT), the most common of the porphyrias, is often
difficult to treat. Deferasirox is a recently approved oral iron chelating agent
which reduces iron stores in patients with chronic iron overload due to blood
transfusions. We sought to determine the efficacy and safety of deferasirox in
a pilot trial for the treatment of patients with PCT. The primary objective was
to eliminate blister formation during the course of the study. Prospective,
open-label, non-comparative study. University-affiliated tertiary health care
center in Dallas, Texas. Ten patients with PCT were treated with deferasirox
for 6 months. The diagnosis was established by documenting the presence of
elevated porphyrins in the urine and a history of developing 3 or more
blisters per month for at least 3 months prior to enrollment. Patients were
treated with 250mg of deferasirox daily with an increase to 500mg daily
after 2 months if new blisters continued to develop. The improvement in
number of blisters at the end of the 6-month treatment period was assessed.
Eight of 10 patients completed the study. All had resolution of their
blistering. Six had a reduction in urinary porphyrins and seven had a
reduction in ferritin levels. The treatment was well tolerated. In this small
pilot study, all patients with PCT who completed the study had resolution of
their blistering and most had a substantial reduction in urinary porphyrins
and ferritin level. Future, larger controlled studies are needed to confirm
these findings. Deferasirox may be a useful alternative to existing treatment
modalities for PCT.
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A new perspective on an old problem: The use of smartphones in
screening for Hansen’s Disease in Trinidad and Tobago
1-K. Maloney/2-S. Lalla/3-J. Kvedar 1-Harvard/2-University of the West
Indies/3-Harvard
In 2005, Trinidad and Tobago contributed the highest proportion of
Hansen’s Disease cases in the Caribbean, with diagnosis occurring on
average, 2-5 years after clinically apparent disease. The World Health
Organization (WHO) states the need to: ‘‘Implement innovative approaches
for case-finding in order to reduce the delay in diagnosis and the occurrence
of grade-2 disabilities.’’ Similar to other Caribbean countries, social workers
visit the homes of people known to have Hansen’s Disease, and screen their
family members for any clinical evidence of disease. The social workers thus
have the greatest contact with the most at risk population for contracting
Hansen’s Disease. We designed a pilot study to train a social worker in using
a smartphone application to screen household contacts of known Hansen’s
Disease cases. The social worker was trained to recognize and take high
quality images of known Hansen’s Disease lesions in the clinic setting using
the smartphone’s 5.2 megapixel camera, and to input photographs and
clinical data into the smartphone software program. After two weeks of
training, the social worker used this format to screen household contacts of
known Hansen’s disease cases in their homes. Encrypted case data was
submitted to a secure website. Broad availability of cellular phone coverage
with associated internet connectivity enabled cases for contacts screened
even in remote locations, to be transmitted in the field. Two dermatologists
accessed the website, reviewed the cases and triaged suspected Hansen’s
Disease cases to a Hansen’s Disease clinic for further evaluation. The social
worker’s detection rate for Hansen’s disease increased from 0.25 cases a
month to 5 cases in a month. This pilot demonstrates that smartphone based
store and forward teledermatology applications can be utilized by low
skilled health workers to take reliable, high quality images in the field, and
increase the detection of Hansen’s Disease.
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Cutaneous lupus erythematosus (CLE) is a chronic inflammatory disorder of
the skin that may be accompanied by systemic manifestations. Currently, no
validated tool exists to confirm self-reports of physician-diagnosed CLE for
use in epidemiologic studies. We have developed and pilot tested the
Cutaneous LUpus ScrEening (CLUSE) tool in an outpatient dermatology
setting at a university center. The CLUSE tool includes features of disease
validation for CLE as well as its various phenotypes. CLUSE is a self-
administered questionnaire with 15 closed-ended questions requiring a
‘‘yes’’ or ‘‘no’’ response, and includes high quality photographs depicting
each of the three main subtypes of CLE (acute, subacute, and chronic). All
English-speaking patients completed the questionnaire without assistance.
The presence or absence of CLE was established by a board-certified
dermatologist. We administered the CLUSE tool to 72 individuals seen in
dermatology clinics. A total of 59 were included in the analysis (10 did not
complete the questionnaire and 3 had a less common variant of CLE not
covered by the photographs). There were 15 participants in the CLE group
and 44 participants in the non-CLE group. We developed scoring algorithms
to assign a diagnosis of CLE. A combination of 6 questions resulted in a
sensitivity of 80% and a specificity of 93.2% for CLE. This pilot study
highlights the need for a validated tool for self-reports of CLE to use in
epidemiologic studies as well as the challenges that exist in designing a tool
for this particular disease. In addition, it suggests that the CLUSE tool can be
useful in excluding patients with non-CLE. The high specificity of the tool
indicates that it may be advantageous in capturing individuals with CLE from
a larger cohort to utilize for epidemiologic studies.
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Co-morbidities associated with Vitiligo: A 10-year retrospective study
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Brigham and Women’s Hospital, Harvard Medical School
Vitiligo is a skin disorder characterized by depigmentation that has a
worldwide prevalence of 0.1-2% and has been associated with several co-
morbidities. Thyroid disorders are commonly associated as are other
endocrinopathies such as Addison’s disease and diabetes mellitus. Perni-
cious anemia, systemic lupus erythematosus, inflammatory bowel disease,
rheumatoid arthritis, and psoriasis also are associated, though the
significance of these is debated. The goal of this study was to characterize
co-morbidities among vitiligo patients seen at Brigham and Women’s
Hospital between January 2000 to June 2010. After Institutional Human
Research Committee approval, all medical records within the Research
Patient Data Repository were evaluated retrospectively using a novel
artificial intelligence program that allowed natural language processing. A
total of 3280 patients with vitiligo were identified using ICD 9 code 709.01,
search for ‘vitiligo’ and ‘vitiligo-related disorders in problems lists. We
selected 300 patients randomly and validated the diagnosis by manually
reviewing medical records. These results were then used to create a model
that was applied to the larger set yielding 2441 validated vitiligo patients. Of
these, 1657 (68%) were diagnosed by dermatologists. Women were more
frequently represented (57.6%) than men. The majority of patients were
White (57%), followed by Hispanic (19%). The mean age was 50.7 years.
565 (23%) had one or more co-morbidities: 263 (11 %) thyroid-related (29
hyperthyroidism, 187 hypothyroidism, 47 thyroiditis), 186 (8%) psoriasis, 72
(3%) rheumatoid arthritis, 53 (2%) systemic lupus, 55 (2%) inflammatory
bowel disease (14 Crohn’s, 33 ulcerative colitis, 8 unspecified), 59 (2%)
alopecia areata, and 20 (1%) Type I diabetes mellitus. No cases of co-morbid
Addison’s disease or pernicious anemia were found. We found a high
prevalence of co-morbidities among individuals with vitiligo presenting to a
teaching hospital in Boston. Physicians caring for vitiligo patients may
consider screening for these co-morbidities.
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